Description
Product details
PT-141 (Bremelanotide) — Cyclic Melanocortin Receptor Agonist
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It acts as a non-selective agonist at melanocortin receptors with notable activity at MC3R and MC4R. Originally derived from work on Melanotan-II, PT-141 has been characterized in more than two decades of preclinical and clinical research examining its action on central melanocortin-receptor pathways and inflammatory signaling.
Mechanism of Action
PT-141 activates melanocortin receptors in the central nervous system, with particularly well-characterized binding to MC4R in the hypothalamus. Preclinical studies show its activation of MC4R modulates dopaminergic signaling in the medial preoptic area, influencing central melanocortin-receptor circuitry distinct from peripheral signaling mechanisms. Additional research has examined its anti-inflammatory action in hemorrhagic shock and ischemia-reperfusion models, mediated through MC1R activation.
Research Applications
- Central melanocortin-pathway research
- Melanocortin receptor signaling studies
- Hypothalamic dopaminergic modulation investigations
- Hemorrhagic shock and inflammation research
- Comparative MC3R / MC4R selectivity studies
Product Specifications
- Quantity: 10mg per vial
- Purity: ≥99% (HPLC verified)
- Molecular Formula: C₅₀H₆₈N₁₄O₁₀
- Molecular Weight: 1025.18 g/mol
- Structure: Cyclic heptapeptide (lactam bridge)
- Form: Lyophilized powder
- Storage: Refrigerate after reconstitution
- Actual Tested Value: 10.57 mg
For research purposes only. Not for human or veterinary use.
